Pub Date : 2025-07-31eCollection Date: 2025-01-01DOI: 10.2337/cd25-0027
Mayer B Davidson
{"title":"Nonlifestyle Treatment of Prediabetes.","authors":"Mayer B Davidson","doi":"10.2337/cd25-0027","DOIUrl":"10.2337/cd25-0027","url":null,"abstract":"","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":"43 4","pages":"579-586"},"PeriodicalIF":0.0,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12547065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145379240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-22eCollection Date: 2025-01-01DOI: 10.2337/cd25-0010
Jodie S Gee, Natalie Rosario, Kevin W Garey, Bernadette Asias-Dinh
The American Diabetes Association recommends continuous glucose monitoring (CGM) to assist people with diabetes in reaching glycemic targets. However, implementation of CGM into routine practice, especially for clinics caring for underserved populations, is not well described. This study assessed the impact of short-term CGM in combination with a pharmacist-led collaborative drug therapy management service on glycemic control in underserved people with diabetes. The pharmacist-led CGM program resulted in improved glycemic control in this population. Future studies should evaluate the scalability and sustainability of this model across diverse clinical practice settings.
{"title":"Effectiveness of Continuous Glucose Monitoring in a Pharmacist-Run Collaborative Drug Therapy Management Service for Underserved Individuals With Diabetes: A Quasi-Experimental Study.","authors":"Jodie S Gee, Natalie Rosario, Kevin W Garey, Bernadette Asias-Dinh","doi":"10.2337/cd25-0010","DOIUrl":"10.2337/cd25-0010","url":null,"abstract":"<p><p>The American Diabetes Association recommends continuous glucose monitoring (CGM) to assist people with diabetes in reaching glycemic targets. However, implementation of CGM into routine practice, especially for clinics caring for underserved populations, is not well described. This study assessed the impact of short-term CGM in combination with a pharmacist-led collaborative drug therapy management service on glycemic control in underserved people with diabetes. The pharmacist-led CGM program resulted in improved glycemic control in this population. Future studies should evaluate the scalability and sustainability of this model across diverse clinical practice settings.</p>","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":"43 4","pages":"554-560"},"PeriodicalIF":0.0,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12547061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145379138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-15eCollection Date: 2025-01-01DOI: 10.2337/cd25-0045
Stephen A Brunton
{"title":"Should DEI DIE?","authors":"Stephen A Brunton","doi":"10.2337/cd25-0045","DOIUrl":"10.2337/cd25-0045","url":null,"abstract":"","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":"43 3","pages":"333"},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-10eCollection Date: 2025-01-01DOI: 10.2337/cd25-0013
Eugene E Wright, Ana Cebrian, Daniel Ngui
This paper reports the expert opinions and recommendations made by primary care physicians (PCPs) to optimize screening and management of chronic kidney disease (CKD) associated with diabetes and presents algorithms to provide a practical and simplified guide for PCPs. Individuals living with type 2 diabetes (T2D) should be screened early and at regular intervals for CKD using both estimated glomerular filtration rate and urinary albumin-to-creatinine ratio testing. The risk of CKD assessed using the Kidney Disease: Improving Global Outcomes heatmap should be reviewed at least annually to optimize treatment to slow progression of CKD. Lifestyle modifications form the foundation of reducing CKD risk in individuals with T2D. A pillared approach to pharmacotherapy (renin-angiotensin system inhibitors, sodium-glucose cotransporter 2 inhibitors, a nonsteroidal mineralocorticoid receptor antagonist [finerenone], and glucagon-like peptide 1 receptor agonists) is recommended in individuals with CKD and T2D. Video 1.Video abstractaf663925-01ab-4645-a362-a879f9639a89cd250013video1.
本文报道了初级保健医生（pcp）对优化糖尿病相关慢性肾脏疾病（CKD）筛查和管理的专家意见和建议，并提出了算法，为pcp提供实用和简化的指南。2型糖尿病（T2D）患者应通过肾小球滤过率和尿白蛋白与肌酐比值检测，尽早并定期筛查CKD。使用肾脏疾病评估CKD的风险：改善全球结果热图应至少每年进行一次审查，以优化治疗以减缓CKD的进展。生活方式的改变是降低T2D患者CKD风险的基础。对于CKD和T2D患者，推荐使用药物治疗的主要方法（肾素-血管紧张素系统抑制剂、钠-葡萄糖共转运蛋白2抑制剂、非甾体矿皮质激素受体拮抗剂[细芬烯酮]和胰高血糖素样肽1受体激动剂）。视频1。视频abstractaf663925 - 01 - ab - 4645 - a362 a879f9639a89cd250013video1。
{"title":"A Primary Care Guide to the Screening and Pharmacologic Management of Chronic Kidney Disease in People Living With Type 2 Diabetes.","authors":"Eugene E Wright, Ana Cebrian, Daniel Ngui","doi":"10.2337/cd25-0013","DOIUrl":"10.2337/cd25-0013","url":null,"abstract":"<p><p>This paper reports the expert opinions and recommendations made by primary care physicians (PCPs) to optimize screening and management of chronic kidney disease (CKD) associated with diabetes and presents algorithms to provide a practical and simplified guide for PCPs. Individuals living with type 2 diabetes (T2D) should be screened early and at regular intervals for CKD using both estimated glomerular filtration rate and urinary albumin-to-creatinine ratio testing. The risk of CKD assessed using the Kidney Disease: Improving Global Outcomes heatmap should be reviewed at least annually to optimize treatment to slow progression of CKD. Lifestyle modifications form the foundation of reducing CKD risk in individuals with T2D. A pillared approach to pharmacotherapy (renin-angiotensin system inhibitors, sodium-glucose cotransporter 2 inhibitors, a nonsteroidal mineralocorticoid receptor antagonist [finerenone], and glucagon-like peptide 1 receptor agonists) is recommended in individuals with CKD and T2D. Video 1.Video abstractaf663925-01ab-4645-a362-a879f9639a89cd250013video1.</p>","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":"43 4","pages":"531-544"},"PeriodicalIF":0.0,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12549410/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145379118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-30eCollection Date: 2025-01-01DOI: 10.2337/cd25-0026
Konstantinos Kitsios, Christina-Maria Trakatelli
{"title":"Automated Insulin Delivery Systems for the Treatment of Elderly People With Type 1 Diabetes: A Case Series and Short Review.","authors":"Konstantinos Kitsios, Christina-Maria Trakatelli","doi":"10.2337/cd25-0026","DOIUrl":"10.2337/cd25-0026","url":null,"abstract":"","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":"43 4","pages":"618-625"},"PeriodicalIF":0.0,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12547060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145379112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-24eCollection Date: 2025-01-01DOI: 10.2337/cd25-0014
Akito Nakatani, Mari Matsushiro, Yuko Yamaguchi, Yutaka Seino, Yuji Yamazaki
{"title":"Fat Quality, Not Just Quantity: Incretin-Based Therapy and Fat Composition in Type 2 Diabetes.","authors":"Akito Nakatani, Mari Matsushiro, Yuko Yamaguchi, Yutaka Seino, Yuji Yamazaki","doi":"10.2337/cd25-0014","DOIUrl":"10.2337/cd25-0014","url":null,"abstract":"","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":"43 4","pages":"626-630"},"PeriodicalIF":0.0,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12547040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145379092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-23eCollection Date: 2025-01-01DOI: 10.2337/cd25-0001
Kelsey A Schmittling
Lower-extremity amputations (LEAs) are a severe complication of diabetes that is associated with nonhealing foot ulcers and peripheral artery disease. Comorbid behavioral health conditions (CBHCs) have been linked to younger age at admission for LEA in people with diabetes. This study investigated the relationship between specific CBHC groups and patient age at presentation for LEA. The presence of CBHCs, median household income <$86,000, primary expected payer other than Medicare, non-White race, and male sex assigned at birth were all correlated with a reduced age of admission in people with LEAs. These findings highlight the interplay between CBHCs and sociodemographic factors that may contribute to earlier hospitalization for LEA in people with diabetes.
{"title":"Age Differences in Lower-Extremity Amputation in People With Diabetes and Behavioral Health Comorbidities.","authors":"Kelsey A Schmittling","doi":"10.2337/cd25-0001","DOIUrl":"10.2337/cd25-0001","url":null,"abstract":"<p><p>Lower-extremity amputations (LEAs) are a severe complication of diabetes that is associated with nonhealing foot ulcers and peripheral artery disease. Comorbid behavioral health conditions (CBHCs) have been linked to younger age at admission for LEA in people with diabetes. This study investigated the relationship between specific CBHC groups and patient age at presentation for LEA. The presence of CBHCs, median household income <b><</b>$86,000, primary expected payer other than Medicare, non-White race, and male sex assigned at birth were all correlated with a reduced age of admission in people with LEAs. These findings highlight the interplay between CBHCs and sociodemographic factors that may contribute to earlier hospitalization for LEA in people with diabetes.</p>","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":"43 4","pages":"525-530"},"PeriodicalIF":0.0,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12547049/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145379088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-20eCollection Date: 2025-01-01DOI: 10.2337/cd25-0035
Hana Kahleova, Joseph Himmelfarb, Cristina Maracine, Arathi Jayaraman, Tatiana Znayenko-Miller, Richard Holubkov, Neal D Barnard
The purpose of this secondary analysis was to assess the potential role of dietary acid load in people with type 1 diabetes. Participants were randomly assigned to either a vegan or a portion-controlled diet group for 12 weeks, and 3-day dietary records were analyzed. Potential renal acid load and net endogenous acid production-both markers of dietary acid load-decreased significantly in the vegan group, but not in the portion-controlled group. Body weight decreased by 5.2 kg in the vegan group, compared with a nonsignificant change in weight in the portion-controlled group. Changes in dietary acid load correlated positively with changes in body weight. The reduction in dietary acid load may partly explain the observed weight loss on a vegan diet.
{"title":"Dietary Acid Load and Body Weight in Type 1 Diabetes: A Randomized Clinical Trial.","authors":"Hana Kahleova, Joseph Himmelfarb, Cristina Maracine, Arathi Jayaraman, Tatiana Znayenko-Miller, Richard Holubkov, Neal D Barnard","doi":"10.2337/cd25-0035","DOIUrl":"10.2337/cd25-0035","url":null,"abstract":"<p><p>The purpose of this secondary analysis was to assess the potential role of dietary acid load in people with type 1 diabetes. Participants were randomly assigned to either a vegan or a portion-controlled diet group for 12 weeks, and 3-day dietary records were analyzed. Potential renal acid load and net endogenous acid production-both markers of dietary acid load-decreased significantly in the vegan group, but not in the portion-controlled group. Body weight decreased by 5.2 kg in the vegan group, compared with a nonsignificant change in weight in the portion-controlled group. Changes in dietary acid load correlated positively with changes in body weight. The reduction in dietary acid load may partly explain the observed weight loss on a vegan diet.</p>","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":"43 4","pages":"520-524"},"PeriodicalIF":0.0,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12547062/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145373223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号